Is this a joke?
Been taking Hemogex for about a week now, and I've already noticed better sleep, increased energy at work (I am at a desk all day and usually dying by early afternoon), a perpetual pump and an odd type of strength increase in the gym...not lifting so much more in terms of lbs (weight is up slightly though) but everything just feels solid. It's like my joints feel better. I have been having some slight tendonitis in my right wrist and bicep, and since taking the hemo it's gotten less and less to where I don't feel it anymore at all....can this stuff be the real deal?? Can anyone post similar experiences with Hemogex?????
Is this a joke?
why would I waste my time posting if this was a joke? I've had decent success with VPX products in the past (i.e. M1T - BUT ANY M1T in the day was prob all the same). But Im no die hard VPX fan by any means...just stating that this product seems to have some effect and was wondering if anyone has had similar benefits. I also noticed very quick finger nail and facial hair growth (just noting that because I've seen others mention it. I've tried alot of supps in my day, so I can tell when I'm getting effects from a supplement.
The reason I ask is that even real GH doesn't show effects that quickly, so you are definitely, 100% for sure experiencing placebo effect.
have you run gh cycles before? If so, what length,doseage etc. until you saw effects?
GHRP-2 has very low oral bioavailability...perhaps 1%. I doubt that they would put 10mgs of GHRP-2 into each drink as this would cost them (even wholesale) more than $10 per drink.
Plus their claim of modifying the terminal to a simple akyl to increase oral bioavailability is doubtfully very effective. There is nothing in the research that indicates that this modification will provide the benefit they claim.
All of this aside ...even IF you got an increase spike of GH release from a drink you won't feel it. GH doesn't work that way.
Enjoy your drink.
But if you want to get GH levels up you need to either inject GH or a growth hormone releasing hormone analog (like CJC-1295) and/or a growth hormone releasing peptide (like GHRP-6).
I've read it actually is quite orally bioavailable.
Here's the very tip of my science:
If after reading my thread you need me to post a study or two or three... to clarify something for a curious mind I don't mind doing that.
I haven't even mentioned the desensitization that rapidly occurs from oral ingestion of GHRPs...
Here is a quick excerpt from one of a few research studies I've read. I can't really validate the sources of any of this info however....
The reason GHRP-2 is best for a science-based formula is because the GH-releasing activity of GHRP-2 is effective even with oral administration. Studies show that the GH releasing effect of GHRP-2 will undergo partial desensitization during continuous infusion, but much less during intermittent oral administration, which is one reason that a science-based formula would be most effective when given in on and off cycles.[/I][/I][/I][/I][/I][/I]
1. Aimaretti G, Corneli G, Razzore P, et al. Usefulness of IGF-1 assay for the diagnosis of GH deficiency in adults. Journal of Endocrinology Investigation 1998 September; 21(8): 506-511.
2. Aloia JF, Zanzi I, Ellis K, et al. Effects of GH in osteoporosis. J Clin Endocrinol Metab 1976; 43:992-999.
3. al-Shoumer KA, et al. Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion, and lipid metabolism in GH-deficient adults. Clin Endocrinol (Oxf) 1998; 48:795-802.
4. Amato G, Carella C, Fazio S, et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. Journal of Clinical Endocrinology and Metabolism 1993; 77:1671-1676.
5. Apaydin H, Ertan S, Ozekmekci S. Broad bean (Vicia faba)--a natural source of L-dopa--prolongs "on" periods in patients with Parkinson's disease who have "on-off" fluctuations. Mov Disord 2000; 15(1): 164-6.
6. Argente J, Garcia-Segura LM, Pozo J, Chowen JA. Growth hormone-releasing peptides: clinical and basic aspects. Horm Res 1996; 46(4-5): 155-9.
7. Arvat E, Camanni F, Ghigo E. Age-related growth hormone-releasing activity of growth hormone secretagogues in humans. Acta Paediatr Suppl 1997 Nov; 423:92-6.
8. Arvat E, Giordano R, Gianotti L, Broglio F, Camanni F, Ghigo E. Neuroendocrinology of the human growth hormone-insulin-like growth factor I axis during ageing. Growth Horm IGF Res 1999; 9:111-115.
9. Bates AS, Evans AJ, Jones P, et al. Assessment of GH status in adults with GH deficiency using serum GH, serum IGF-1 and urinary GH excretion. Clinical Endocrinology 1995 April; 42(4): 425-430.
10. Bengtsson BA, Eden S, Lonn L, et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993; 76:309-317.
11. Berelowitz M, Szabo M, Frohman LA, Firestone S, Chu L. Somatomedin C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science 1981; 212:1279-1281.
12. Beth-EI D. Rejuvenating effects of natural L-dopa content in Vicia Faba golden beans. Israel Journal of Anti-Ageing Research 1990; 4:9-11.
13. Binnerts A, Swart GR, Wilson JH, Hoogerbrugge N, Pols HA, Birkenhager JC, et al. The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clin Endocrinol (Oxf) 1992; 37:79-87.
14. Borst SE and Lowenthal DT: Role of IGF-1 in muscular atrophy of aging. Endocrine 7:61-63, 1997.
15. Bowers CY. GH releasing peptides--structure and kinetics. J Pediatr Endocrinol 1993 Jan-Mar; 6(1): 21-31.
16. Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci 1998; 54:1316-1329.
17. Bowers CY, Granda-Ayala R. GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans. J Pediatr Endocrinol Metab 1996 Jun; 9 Suppl 3:261-70.
18. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984 May; 114(5): 1537-45.
19. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, et al. 1990 Growth hormone (GH)-releasing peptide stimulates GH release in normal man and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990;70:975–982.
20. Brainum J. GH new compounds that can blast your growth hormone to new levels. Ironman Magazine 1998 June;22-25.
21. Brown GL, Nanney LB, Griffen J, et al. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 1989; 321(2):76-79.
22. Camanni F, Ghigo E, Arvat E. Growth hormone-releasing peptides and their analogs. Front Neuroendocrinol 1998 Jan;19(1):47-72.
23. Carlson HE, Miglietta JT, Roginsky MS, et al. Stimulation of pituitary hormone secretion by neurotransmitter amino acids in humans. Metabolism 1989;28:1179-82.
24. Carter-Su C, Schwartz J, Smit LS. Molecular mechanism of growth hormone action. Annu Rev Physiol 1996;58:187-207.
25. Cavagnini F, Invitti C, Pinto M, et al. Effect of acute and repeated administration of gamma aminobutryic acid (GABA) on growth hormone and prolactin secretion in man. Acta Endocrinologica 1980; 93:149-154.
26. Cenni A, et al. Pharmacological properties of a nootropic agent of endogenous origin: D-Pyroglutamic Acid. Journal of Drug Development 1988;1:157-62.
27. Cerami A, Vlassara H, Browlee M. Glucose and aging. Sci Am 1987;256:90-96.
28. Chapman IM, Bach MA, Cauter EV, et al. Oral administration of a growth hormone secretagogue (MK-0677) to older adults enhances pulsatile GH release and restores young adult IGF-I concentrations. J Clin Endocrinol Metab 1996;81:4249-4257.
29. Cheng J, Wu TJ, Butler B, Cheng K. Growth hormone releasing peptides: a comparison of the growth hormone releasing activities of GHRP-2 and GHRP-6 in rat primary pituitary cells. Life Sci 1997;60(16):1385-92.
30. Colao A, Merola B, Ferone D, Lombardi G. Acromegaly. J Clin Endocrinol Metab. 1997;82:2777-2781.
31. Corpas E, et al. Human growth hormone and human aging. Endocr Rev 1993;14:20-39.
32. Cummons DR, Underwood LE. Nutritional regulation of IGF-I, and IGF binding proteins. Annu Rev Nutr 1991;11:393-412.
33. Cuneo RC, Salomon F, Wiles CM, et al. Growth hormone treatment in growth hormone deficient adults. II. Effects on exercise performance. Journal of Applied Physiology 1991;70:695-700.
34. Daughaday WH. Evolving concepts of GH and IGF-I regulation of skeletal growth. Endocrine 1994;2:767-769.
35. Deghenghi R, Boutignon F, Luono M, Grilli R, Guidi M, Locatelli V. Small peptides as potent releasers of growth hormone. J Pediatr Endocrinol Metab 1995;8:311–313.
36. Eichman JD, Robinson JR. Mechanistic studies on effervescence-induced permeability enhancement. Pharm Res 1998;15(6):925-930.
37. Ellakim A, Oh Y, Cooper DM. Effect of single wrist exercise on fibroblastic growth factor-, insulin-like growth factor, and growth hormone. Am J Physiol Integr Comp Physiol 2000 Aug; 279(2):R548-53.
38. Farina E, Piu P, Strinna L. Extraction of L-DOPA from Vicia faba L. and other plants of the leguminous genera. Boll Soc Ital Biol Sper 1974 Apr 30;50(8):508-11
39. Fleisher D, Niemiec SM, Oh CK, Hu Z, Ramachandran C, Weiner N. Topical delivery of growth hormone releasing peptide using liposomal systems: an in vitro study using hairless mouse skin. Life Sci 1995;57:1293.
40. Freundlich B, Bamalaski JS, Neilson E, Jimenes SA. Regulation of fibroblast proliferation and collagen synthesis by cytokines. Immunol Today 1986;7: 303-307.
41. Fried R, Merrell WC. The Arginine Solution, Warner Books, 1999.
42. Furlanetto RW. Insulin-like growth factor measurements in the evaluation of growth hormone secretion. Hormonal Research 1990;33 Suppl 4:25-30.
43. Gelato MC. Aging and immune function: a possible role for growth hormone. Hormonal Research 1996; 45(1-2): 46-9.
44. Gelato MC, Merriam GR. Growth hormone-releasing hormone. Annu Rev Physiol 1986;48:569-591.
45. Ghigo E, Arvat E, Camanni F. Orally active growth hormone secretagogues: state of the art and clinical perspectives. Ann Med 1998 Apr;30(2):159-68.
46. Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol 1997 May;136(5):445-60.
47. Ghigo E, Arvat E, Rizzi G, Bellone J, Nicolosi M, Bofano GM et al. Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration. J Endocrinol Invest 1994; 17:157-162.
48. Ghigo E, Arvat E, Valente F. Arginine reinstates the somatotrope responsiveness to intermittent growth hormone-releasing hormone administration in normal adults. Neuroendocrinology 1991; 54:291-294.
49. Ghigo E, Ceda GP, Valcavi R, Goffi S, Zini M, Mucci M et al. Low doses of either intravenously or orally administered arginine are able to enhance growth hormone response to growth hormone releasing hormone in elderly subjects. J Endocrinol Invest 1994; 17:113-122.
50. Ghigo E, Goffi S, Nicolois M, Arvat E, Procopio M, Bellone J et al. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man. J Clin Endocrinol Metab 1990; 71:1481-1485.
51. Goldman JK, Bressler R. Growth hormone stimulation of fatty utilization by adipose tissue. Endocrinology 1967;81:1306.
52. Gondo RG, Aguiar-Oliveira MH, Hayashida CY, Toledo SP, Abelin N et al. Growth hormone-releasing peptide-2 stimulates GH secretion in GH-deficient patients with mutated GH-releasing hormone receptor. J Clin Endocrinol Metab 2001 Jul;86(7):3279-83.
53. Gospodarowicz D, Cheng J, Lui GM, Baird A, Esch F, Bohlen P. Angiogenic factor is related to fibroblast growth factor. Endocrinology 1985;117: 2383-2391.
54. Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G. Structural characterization and biological function of fibroblast growth factor. Endocrinol Rev 1987;8: 95-114.
55. Grinnell F, Lamke CR. Reorganization of hydrated collagen lattices by human skin fibroblasts. J Cell Sci 1984;66: 31.
56. Grioli S, et al. Pyroglutamic acid improves the age associated memory impairment. Fundamental and Clinical Pharmacology 1990;4:169-73.
57. Hall K, Sara VR. Somatomedin levels in childhood, adolescence and adult life. J Endocrinol Metab 1984;13:91-112.
58. Haltiwanger, S. Winning in the New World: With help from the power of anti-aging peptides and hormones. 2002; 1-9:10-66.
59. Hartman ML, Farello G, Pezzoli SS, Thorner MO. Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men. J Clin Endocrinol Metab 1992;74:1378–1384.
60. Hashizume T, Tanabe Y, Ohtsuki K, Mori A, Matsumoto N, Hara S. Plasma growth hormone (GH) responses after administration of the peptidergic GH secretagogue KP102 into the oral cavity, rumen, abomasum and duodenum in adult goats. Domest Anim Endocrinol 2001 Jan;20(1):37-46.
61. Hendrix DK, Klien TE, Kuntz ID. Macromolecular docking of a three-body system: the recognition of human growth hormone by its receptor. Protein Science 1999 May; 8(5): 1010-1022.
62. Ho KK. Metabolic actions of growth hormone in man. Endocr J 1996;43(suppl):S57-S63.
63. Ho KY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24 hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987;64:51-58.
64. Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994;78:669-74.
65. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996;273:974-977.
66. Hull KL, Harvey S. Growth hormone resistance: clinical states and animal models. J Endocrinol 1999;163:165-172.
67. Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of GH secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 1991;73:1081-1088.
68. Isidori A, Lo Monaco A, Cappa M. A study of growth hormone release in man after oral administration of amino acids. Current Medical Research Opinion 1981;7:75-81.
69. Iwasaki K, Mano K, Ishihara M, et al. Effects of ornithine or arginine administration on serum amino acid levels. Biochemistry International 1987;14:971-6.
70. Johnston DG, Bengtsson BA. Workshop report: the effects of growth hormone and growth hormone deficiency on lipids and the cardiovascular system. Acta Endocrinologica 1993;128 (Suppl 2):69-70.
71. Jorgenson PH, Andreassen TT, Jorgensen KD. Growth hormone influences collagen deposition and mechanical strength of intact rat skin: a dose response study. Acta Endocrinol 1989; 120:767-772.
72. Kasi K, et al. Stimulatory effect of glycine on human growth hormone secretion. Metabolism 1978 Feb;27(2):201-08.
73. Kempster PA, Walquist ML. Dietary factors in the management of Parkinson’s disease. Nutr Rev 1994;52:51-59.
74. Kreider RB. Dietary supplements and the promotion of muscle growth with resistance training Sports Medicine 1999;27:97-110.
75. Labram EK, Wilkin TJ. Growth hormone deficiency in adults and its response to GH replacement. QJM 1995;88:391-399.
76. Lanzi R, et al. Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects. Metabolism: Clinical & Experimental 1999; 48(9):1152-6.
77. Lanzi R, Tannenbaum GS. Time course and mechanism of growth hormone's negative feedback effect on its own spontaneous release. Endocrinology 1992; 130:780-788.
78. Laron Z. Growth hormone secretagogues: clinical experience and therapeutic potential. Drugs 1995;4:595–601.
79. Lieberman SA, Hoffman AR. Growth hormone deficiency in adults: Characteristics and response to GH replacement. J Pediatr 1996;128:S58-S60.
80. Lynch JB. (1989) Enhancement of wound healing by topical treatment with epidermal growth factor. N EngI J Med 1989;321:76.
81. Maas HCM, de Vries WR, Maitimu I, Bol E, Bowers CY, Koppeschaar HP. Growth hormone responses during strenuous exercise: the role of GH-releasing hormone and GH-releasing peptide-2. Med Sci Sports Exerc 2000 Jul;32(7):1226-32.
82. Marcus R, Hoffman AR. Growth hormone as therapy for older men and women. Annu Rev Pharmacol Toxicol 1998;38:45-61.
83. Matsunaga SGN, Hidaka S, Hidari H. Characterization of growth hormone secretion responsiveness to growth hormone-releasing peptide-2 (GHRP-2 or KP102) in calves. Endocrine J 1996;43:291-298.
84. McGauley GA, Cuneo RC, Salomon F, et al. Psychological well-being before and after growth hormone treatment in adults with growth hormone deficiency. Hormone Research 1990;33 (suppl 4):52-54.
85. McGee GS, Davidson JM, Buckley A et al. Recombinant basic fibroblast growth factor accelerates wound healing. J Surg Res 1988;45: 145-153.
86. Mericq V, Cassorla F, Garcia H, et al. Growth hormone (GH) responses to GH-releasing peptide and to GH-releasing hormone in GH-deficient children. J Clin Endocrinol Metab 1995;80:1681-1684
87. Mericq V, Cassorla F, Salazar T, Avila A, Iniguez G, Bowers CY, Merriam GR. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab 1998 Jul;83(7):2355-60.
88. Merriam G, Buchner D, Prinz P, Schwartz R, Vitiello M. Potential applications of GH secretagogues in the evaluation and treatment of the age-related decline in growth hormone secretion. Endocrine 1997;7:49-52.
89. Merimee TJ, Rabinowitz D, Fineberg SE. Arginine-initiated release of human growth hormone. N Engl J Med 1969; 280:1434-8.
90. Micic D, Popovic V, Doknic M, Macut D, Dieguez C, et al. Preserved growth hormone (GH) secretion in aged and very old subjects after testing with the combined stimulus GH-releasing hormone plus GH-releasing hexapeptide-6. The Journal of Clinical Endocrinology & Metabolism 1998;83(7):2569-2572.
91. Momany FA, Bowers CY, Reynolds GA, Chang D, Hong A, Newlander K. Design, synthesis and biological activity of peptides which release growth hormone, in vitro. Endocrinology 1981;108:31–39.
92. Momany FA, Bowers CY, Reynolds GA, Hong A, Newlander K. Conformational energy studies and in vitro and in vivo activity data on growth hormone-releasing peptides. Endocrinology 1984;114:1531–1536.
93. Muccioli G, Broglio F, Valetto MR, Ghe C, Catapano F, et al. Growth hormone-releasing peptides and the cardiovascular system. Ann Endocrinol (Paris) 2000 Feb;61(1):27-31.
94. Murphy LJ, Seneviratne C, Moreira P, et al. Enhanced expression of insulin-like growth factor-binding protein-I in the fasted rat: the effects of insulin and growth hormone administration. Endocrinology 1991 February; 128(2): 689-96.
95. Nass R, Huber RM, Klauss V, et al. Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood. J Clin Endocrinol Metab 1995 Feb 80(2):552-7.
96. Ninh NX, Thissen JP, Maiter D, Adam E, Mulumba N, Ketelslegers JM. Reduced liver IGF-I gene expression in young zinc deprived rats is associated with a decrease in liver GH receptors and serum GH binding protein. J Endocrinol 1995;144:449-454.
97. O'Halloran DJ, Tsatsoulis A, Whitehouse RW, et al. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. Journal of Clinical Endocrinology and Metabolism 1993;76:1344-1348.
98. Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab 1998 Apr;83(4):1186-9.
99. Panossian V, Liu SH, Lane JM, Finerman GA. Fibroblastic growth factor and epidermal growth factor receptors in ligament healing. Clin Orthop 1997 Mar;HD(342):173-80.
100. Pavlov EP, Harman SM, Merriam GR, et al. Responses of growth hormone (GH) and somatomedin-C to GH-releasing hormone in healthy aging men. J Clin Endocrinol Metab 1986;62:595-600.
101. Pierce GF, Tarpley JE, Yanagiharo D, et al. Platelet-derived growth factor (BB homodimer). transforming growth factor-B1, and basic fibroblast growth factor in dermal wound healing. neovessel and matrix formation and cessation of repair. Am J Pathol 1992;140:1375-1388.
103. Pihoker C, Badger TM, Reynolds GA, Bowers CY. Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature. Journal of Endocrinology 1997;155:79-86.
104. Pihoker C, Kearns GL, French D, Bowers CY. Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children. J Clin Endocrinol Metab 1998 Apr;83(4):1168-72.
105. Pihoker C, Middleton R, Reynolds GA, Bowers CY, Badger TM. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature. J Clin Endocrinol Metab 1995 Oct;80(10):2987-92.
106. Phung LT, Sasaki A, Lee HG, Vega RA, Matsunaga N, et al. Effects of the administration of growth hormone-releasing peptide-2 (GHRP-2) orally by gavage and in feed on growth hormone release in swine. Domest Anim Endocrinol 2001 Jan;20(1):9-19.
That's not science. GHRP-2 like all the GHRPS are minimally orally bioavailable. But the percentage is so low that Merck spent a lot of time develpoing MK-0677 a non-peptide GHS-mimetic that IS highly bioavailable.
Yes as I noted in my article desensitaztion does occur via constant infusion. Do you know what constant infusion is bro?
It is where an IV is hooked up and a drug/peptide is continually administered. That has nothing to do with a subcutaneous injection....which if given at intervals is intermittent.
In addition GHRPs by the oral administration route exhibit a delay in exciting the hypothalamic neurons probably because they do not cross the blood brain barrier as rapidly. This means that they wouldn't act as quickly as adminstration by subcutaneous injection.
Are you familiar with the term tachyphylaxia? That is what occurs when GHRP-2 and other GHS are administered orally. They loose effectiveness even when dosed intermittently. This is an effect that is common to a lot of oral medications. By-the-way it basically means "a decreased response to a medicine given over a period of time so that larger doses are required to produce the same response."
By the way that site that is serving as your scientific source...the one that use the term "science-based formula"...it is NOT a scientific journal or medical journal. They sell you products based on this "science-based formula" language.
You may wish to read Roy G. Smith's account of his research at Merck in discovering MK-0677 a highly orally bioavailable GHS. It can be found in the following citation:
Peptidomimetic Regulation of Growth Hormone Secretion
Endocr. Rev., Roy G. Smith..., Oct 1997; 18: 621 - 645.
Why would Merck go to all this trouble if GHRP-2 was so highly orally bioavailable....hmmmm....here is a sentence or two from that article...
The peptide GHRP-6 was of ideal size, but because its receptor had not been identified, and cell lines responsive to GHRP-6 were unknown, high volume screening for a peptidomimetic was impractical. Based on these considerations, investigators modified the structure of GHRP-6 and identified more potent peptides (4, 5, 6, 18). For example, activity was enhanced by replacing D-Trp2 by D-2-(2-napthyl)alanine and His by D-alanine to furnish GHRP-2 (D-Ala-D-2 Nal-Ala-Trp-D-Phe-Lys-NH2) (5). However, the peptides still had low oral bioavailability....
I added the bold of course.
ow you got alot of time on your hands bro! thx for the info though......you studying your phd or what?
OK I dont mean to drag this out too long, but I'm just trying to validate the fact that I've read studies out there that confirm GHRP-2 may be orally bioavailable. I am no scientist nor am I attempting to be one. You've given me some good information and now have my mind going as I am now addicted to researching this toic...thanks alot!!
I don't know what amount of GHRP-2 is even contained in Hemogex, nor do I or does anyone else in this forum truly know how well it works.....anyway one more quote from a study I was just reading.
In this protocol we administered GHRP-2 by sc injections, in part because of limited supplies and limited safety information for children by other routes at the time of the study, in part to allow direct comparison with our previous studies using sc GHRH. Among the potential advantages of GHRP-2 treatment is the possibility of oral administration, because of its small size and resistance to digestive proteolysis, although the doses employed are necessarily much higher. This is usually viewed as a matter of convenience and patient acceptance, but the results of our study suggest other potential advantages to that route. Given subcutaneously, GHRP-2 has only a brief effect and does not elevate pulsatile GH secretion through the night. A sustained-release formulation might have such an effect, but it is also possible that oral GHRP-2 will have a longer duration of action based upon the kinetics of absorption, and sustained-release oral preparations may be easier to formulate than long-acting injections.
Last question now...so what would you suggest as the most efficient means to increase GH levels safely without shutdown after prolonged useage?
It does have very good feedback on 1fast so who knows, I noticed hair and nails growing faster on PowerFull within the first week so yes it is very possible for him to being feeling it as fast as he says.
im interested in powerfull also bro, how did you like it?? Also, by what method does gh increase occurr with this type of product? I hear alot about powerfull and have taken alot of supps, but idk anything about powerfull.
Sorry bro but after this I'm done with this thread. I can tell by your last question that you never read the guides I wrote and posted at: http://anabolicminds.com/forum/igf-1...dat-s-cjc.html
Why bother arguing with someone about something which is a basic established fact. GHRPs have a low oral bioavailability. They are orally bioavailabe...but not highly so. The oral bioavailability is less then 1%. There are studies where it was administered orally at I believe 25mg per dose.
They are also bioavailable via intranasal administration.
Again the dose has to be much higher than that used by injection.
Did you read the complete study you posted?
They used subcutaneous injection not oral administration.
Here this is from the "Subjects and Methods" section of that study:
Parents were instructed in sc injection technique using insulin syringes. After baseline assessment, patients were treated for successive 2-month periods with daily bedtime injections of GHRP-2 in doses of 0.3, 1.0, and 3.0 µg/kg. During a final 2-month period, patients received both 3.0 µg/kg GHRP-2 and 3.0 µg/kg GHRH at separate injection sites. Patients and parents were instructed to report any side effects and remained in frequent contact with study personnel.
You want to read a study where a GHRP was used orally? Here is an abstract where GHRP-6 was given orally. Note the dose 300mcg/kg which means 30mg for a 100kg man. You do realize that the retail price of a single dose using this protocol would mean about $300.
The result was less GH release than that illicited by GHRP-6 given subcutaneously at 1mcg/kg or 100mcg....which by-the-way is 300 times smaller than the dose given here by oral administration.
Here is the abstract:
European Journal of Endocrinology, Vol 133, Issue 4, 425-429
Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature
Growth hormone-releasing peptide 6 (GHRP-6) is a synthetic hexapeptide with a potent GH-releasing activity after intravenous, subcutaneous, intranasal and oral administration in man. Previous data showed its activity also in some patients with GH deficiency. The aim of our study was to verify the GH-releasing activity of oral GHRP-6 administration on GH secretion in children with normal short stature.
The effect of oral GHRP-6 (300 micrograms/kg) was compared with that of the maximally effective dose of intravenous GH-releasing hormone (GHRH-29, 1 microgram/kg). As the GHRH-induced GH rise in children is potentiated by arginine (ARG), even when administered by oral route at low dose (4 g), we studied also the interaction of oral GHRP-6 and ARG administration.
We studied 13 children (nine boys and four girls aged 6.2-10.5 years, pubertal stage I) with normal short stature (height less than -2 SD score; height velocity more than -2 SD score; normal bone age; insulin-like growth factor I > 70 micrograms/l).
In a first group of children (N = 7), oral GHRP-6 administration induced a GH response (mean +/- SEM; peak at 60 min vs baseline: 18.8 +/- 3.0 vs 1.1 +/- 0.3 micrograms/l, p < 0.0006; area under curve: 1527.3 +/- 263.9 micrograms l-1 h-1) which was similar to that elicited by GHRH (peak at 45 min vs baseline: 20.8 +/- 4.5 vs 2.2 +/- 0.9 micrograms/l, p < 0.007; area under curve: 1429.4 +/- 248.2 micrograms l-1 h-1).(ABSTRACT TRUNCATED AT 250 WORDS)
Here is a quote from a study by the discoverer of GHRPs. Keep in mind 1ug = 1 mcg. Taken from:
"The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration"
CY Bowers, DK Alster, and JM Frentz, J. Clin. Endocrinol. Metab., Feb 1992; 74: 292 - 298
...Since 300 ug/kg oral GHRP released about the same amount of GH as 1 ug/kg, iv, in normal men, it was calculated that oral GHRP has about 0.3% the activity of iv GHRP....
So GHRPs end up being 333 times less effective when taken orally. That is LOW bioavailability. Yes SOME bioavailability (0.3%) but it is very LOW.
Food for thought:
Every single individual will act differently to every single substance
VPX may have a better delivery system than in these studies
And I'll end by saying this, my wife is an ICU nurse and she tells me some ****ed up stories of things that people do to end up on their death beds, and you'd be amazed at how little, or sometimes how much people need to OD on certain substances before their body even reacts to them.....Im not going into detail here because its off topic, but just keep in mind that science is an evolving thing and a study based on a few subjects makes nothing fact, including VPX's assessment of their trial results.
I'm simply posting my results with a products, and was interested to see if anyone had similar results.
Thank you for your input it actually was fairly interesting reading.
I have gone thru a bottle of PowerFULL. The only thing that I noticed was a deeper sleep via my waking up groggy and remembering dreams which I rarely do even though I have no trouble sleeping. Everything I have read and heard about HGH from people that have actually used it and not from studies which mostly have their own agendas...HELLO? is that it takes 3-6 months to notice results from injections.
In summary...increasing normal HGH production would take take the same amount of time to see the results.
The Placebo effect is more real than immediate results. I see it all the time. People are brainwashed for instant gratification. The reason you hear soo much about Powerfull is because it makes people sleep better...not unlike ZMA, and many people have trouble sleeping...as you know.